Enterprise record

Dyne Therapeutics, Inc.

Public governance Claims and source records for this enterprise.

Alpha ID: alpha:company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2Version: public-1As of: unavailable

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Identity

unclaimed

Evidence

source reported

Evaluation

Unknown

Monitoring

Unknown

Authority

Unknown

Freshness

Observed 2026-09-27

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 27, 2026

    Supports 3 claims
    • Legal Name: Dyne Therapeutics, Inc. · Claim reviewed: Sep 27, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 27, 2026
    • Published Fact: US · Claim reviewed: Sep 27, 2026

  2. SEC DEF 14A 0001193125-26-173655

    sec def 14a · Source published: Apr 23, 2026 · Retrieved: Sep 6, 2026

    Supports 6 claims
    • Leadership Role: Jason Rhodes: Chairman of the Board · Claim reviewed: Sep 27, 2026
    • Leadership Role: John G. Cox: Chief Executive Officer, President and Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Douglas Kerr: Chief Medical Officer · Claim reviewed: Sep 27, 2026
    • Leadership Role: Erick Lucera: Chief Financial Officer and Treasurer · Claim reviewed: Sep 27, 2026
    • Leadership Role: Johanna Friedl-Naderer: Chief Commercial Officer · Claim reviewed: Sep 27, 2026
    • Leadership Role: John G. Cox: Chief Executive Officer and President · Claim reviewed: Sep 27, 2026

  3. DEF 14A dyn-20260422.htm

    sec proxy · Source published: Apr 23, 2026 · Retrieved: Sep 2, 2026

    Supports 8 claims
    • Leadership Role: Brian Posner: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Carlo Incerti: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Catherine Stehman-Breen: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: David Lubner: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Dirk Kersten: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Edward Hurwitz: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Johanna Friedl-Naderer: Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Vikram Karnani: Director · Claim reviewed: Sep 27, 2026

  4. DYN DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 16, 2026

    Supports 3 claims
    • Leadership Role: Jeremy K. Cox: Chief Executive Officer, President and Director · Claim reviewed: Sep 27, 2026
    • Leadership Role: Oxana Beskrovnaya: Chief Innovation Officer · Claim reviewed: Sep 27, 2026
    • Leadership Role: Richard Scalzo: Senior Vice President, Head of Finance and Administration · Claim reviewed: Sep 27, 2026